Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Terminated
Celgene Corporation
Phase 2
2009-05-06
The goal of this clinical research study is to learn if lenalidomide, when given with a stem
cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to
control CLL. The safety of this treatment combination will also be studied.
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Terminated
M.D. Anderson Cancer Center
Phase 2
2009-05-06
The goal of this clinical research study is to learn if lenalidomide, when given with a stem
cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to
control CLL. The safety of this treatment combination will also be studied.
Busulfan and Cyclophosphamide Followed By ALLO BMT
Terminated
Masonic Cancer Center, University of Minnesota
N/A
2013-01-01
This is a treatment guideline to allow routine clinical data to be collected and maintained
in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as
part of the historical database maintained by the department.
Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting
AbbVie
Phase 2
2017-06-16
This phase II trial studies how well venetoclax and ibrutinib work in treating participants
with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in
chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving venetoclax and ibrutinib may work better in treating
participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.